Isaac K. Quaye

Prof. Isaac K. Quaye


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Parasitology International
Verified
Journal Article
Open access
IQIsaac K. Quaye
Isaac K. Quaye
LALarysa Aleksenko
Larysa Aleksenko
COClaude Oeuvray
Claude Oeuvray
DYDelenasaw Yewhalaw
Delenasaw Yewhalaw
NDNancy Duah
Nancy Duah
BGBeatrice Greco
Beatrice Greco
The recent World Malaria report shows that progress in malaria elimination has stalled. Current data acquisition by NMCPs depend on passive case detection and clinical reports focused mainly on Plasmodium falciparum (Pf). In recent times, several countries in sub-Saharan Africa have reported cases of Plasmodium vivax (Pv) with a considerable number being Duffy negative. The burden of Pv and Plasmodium ovale (Po) appear to be more than acknowledged. Similarly, the contribution of asymptomatic malaria in transmission is hardly considered by NMCPs in Africa. Inclusion of these as targets in malaria elimination agenda is necessary to achieve elimination goal, as these harbor hypnozoites. The Pan African Vivax and Ovale Network (PAVON) is a new consortium of African Scientists working in Africa on the transmission profile of Pv and Po. The group collaborates with African NMCPs to train in Plasmodium molecular diagnostics, microscopy, and interpretation of molecular data from active surveys to translate into policy. Details of the mission, rational and modus operandi of the group are outlined.

2 June 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
TMThato Motshoge
Thato Motshoge
DHDaniel Haiyambo
Daniel Haiyambo
RARuth Ayanful-Torgby
Ruth Ayanful-Torgby
LALarysa Aleksenko
Larysa Aleksenko
DNDavies Ntebela
Davies Ntebela
IQIsaac K. Quaye
Isaac K. Quaye
: In 2016, we reported the presence of Plasmodium vivax in Botswana through active case detection. A real-time PCR was used during a similar study in 10 districts to assess changes in the P. vivax prevalence. We assessed 1,614 children (2–13 years of age) for hemoglobin (Hb; g/dL) and Plasmodium parasites. The median age of all participants was 5.0 years (25th percentile, 3 years; 75th percentile, 8 years). The median Hb (g/dL) level was 12.1, but 18.3% of the participants had anemia (Hb < 11.0 g/dL); these participants were clustered in the younger than 5 years age group in all districts (P < 0.001). The risk of anemia decreased with age 5 years or older (odds ratio [OR], 0.26; 95% confidence interval [CI], 0.197–0.34; P < 0.001). The prevalence rates of Plasmodium parasites were as follows: P. vivax, 12.7%; P. falciparum, 12.7%; P. malariae, 0.74%; and P. ovale (P. ovale curtisi), 0.68%. Mixed infection rates were as follows: P. falciparum and P. vivax, 2.35%; P. falciparum and P. ovale curtisi, 0.56%; P. vivax and P. malariae, 0.06%; and P. falciparum and P. malariae, 0.68%. The infections were largely asymptomatic (99.6%). Using logistic regression, the risk of infection with P. vivax was highest in Kweneng East (OR, 6.2; 95% CI, 2.9–13.1), followed by South East (OR, 5.6; 95% CI, 2.5–12.3) and Ngami (OR, 5.1; 95% CI, 2.2–12.0). Compared to the risk of infection for children younger than 5 years, the risk of infection decreased for children 5 years or older in regions with high rates of P. vivax and P. falciparum infections. P. vivax and P. falciparum have expanded within the asymptomatic population in Botswana; therefore, careful attention is required for their elimination.

21 August 2021 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
DHDaniel Hosea Haiyambo
Daniel Hosea Haiyambo
LALarysa Aleksenko
Larysa Aleksenko
DMDavies Mumbengegwi
Davies Mumbengegwi
RBRonnie Bock
Ronnie Bock
PUPetrina Uusiku
Petrina Uusiku
IQIsaac K. Quaye
Isaac K. Quaye
In a previous study, using a molecular approach, we reported the presence of P. vivax in Namibia. Here, we have extended our investigation to the Duffy antigen genetic profile of individuals of the same cohort with and without Plasmodium infections. Participants with P. vivax (n = 3), P. falciparum (n = 23) mono-infections and co-infections of P. vivax/P. falciparum (n = 4), and P. falciparum/P. ovale (n = 3) were selected from seven regions. Participants with similar age but without any Plasmodium infections (n = 47) were also selected from all the regions. Duffy allelic profile was examined using standard PCR followed by sequencing of amplified products. Sequenced samples were also examined for the presence or absence of G125A mutation in codon 42, exon 2. All individuals tested carried the − 67 T > C mutation. However, while all P. vivax infected participants carried the c.G125A mutation, 7/28 P. falciparum infected participants and 9/41 of uninfected participants did not have the c.G125A mutation. The exon 2 region surrounding codon 42, had a c.136G > A mutation that was present in all P. vivax infections. The odds ratio for lack of this mutation with P. vivax infections was (OR 0.015, 95% CI 0.001–0.176; p = 0.001). We conclude that P. vivax infections previously reported in Namibia, occurred in Duffy negative participants, carrying the G125A mutation in codon 42. The role of the additional mutation c.136 G > A in exon 2 in P. vivax infections, will require further investigations.

Verified
Journal Article
Open access
PDF file
IQIsaac K. Quaye
Isaac K. Quaye
LALarysa Aleksenko
Larysa Aleksenko
GPGiacomo Maria Paganotti
Giacomo Maria Paganotti
EPElias Peloewetse
Elias Peloewetse
DHDaniel Haiyambo
Daniel Haiyambo
TCthe PAVON Consortium
the PAVON Consortium
The global malaria community has picked up the theme of malaria elimination in more than 90% of the world’s population in the next decade. Recent reports of Plasmodium vivax (P. vivax) in sub-Saharan Africa, including in Duffy-negative individuals, threaten the efforts aimed at achieving elimination. This is not only in view of strategies that are tailored only to P. falciparum elimination but also due to currently revealed biological characteristics of P. vivax concerning the relapse patterns of hypnozoites and conservation of large biomasses in cryptic sites in the bone marrow and spleen. A typical scenario was observed in Botswana between 2008 and 2018, which palpably projects how P. vivax could endanger malaria elimination efforts where the two parasites co-exist. The need for the global malaria community, national malaria programs (NMPs), funding agencies and relevant stakeholders to engage in a forum to discuss and recommend clear pathways for elimination of malaria, including P. vivax, in sub-Saharan Africa is warranted.

3 July 2023 in Biochemical Genetics
Verified
Journal Article
Closed access
PDF file
GAGrace K. Ababio
Grace K. Ababio
IEI. Ekem
I. Ekem
JAJ. Acquaye
J. Acquaye
SOS. Y. Oppong
S. Y. Oppong
AAA. G. B. Amoah
A. G. B. Amoah
IQIsaac K. Quaye
Isaac K. Quaye

14 May 2019 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
DHDaniel H Haiyambo
Daniel H Haiyambo
AIAlex Ilunga
Alex Ilunga
RNRuth Nangombe
Ruth Nangombe
GAGrace Ababio
Grace Ababio
THToini Hatuikulipi
Toini Hatuikulipi
IQIsaac K. Quaye
Isaac K. Quaye
Background: Namibia has made significant gains in the fight against malaria, with a target of elimination by 2023. We examined the genotype and allele frequencies of glucose-6-phosphate dehydrogenase (G6PD) deficiency to inform decisions on primaquine use, as we recently detected clusters of Plasmodium ovale curtisi in Kavango.Methods: A multistaged cross-sectional sampling method was used to enrol 212 children 2–9 y of age from schools and clinics in the Okavango and Zambezi regions of northern Namibia. Genotypes for the 202 G→A and 376 A→G mutations were assigned by polymerase chain reaction restriction fragment length polymorphism.Results: Of the 212 subjects enrolled, genotypes were available for 210, made up of 61 males and 149 females. G6PD-deficient males (hemizygotes) and females (homozygotes) constituted 3.27% (2/61) and 0.0% (0/149), respectively. Female heterozygotes (AA− and BA−) constituted 10.07% (15/149), while G6PD wild-type males (with A or B haplotype) and females (with AA, BB or AB haplotypes) consisted of 96.72% (59/61) and 89.93% (134/149), respectively. The A−, A and B allele frequencies were 0.0474, 0.3036 and 0.6490, respectively. Hardy–Weinberg equilibrium tests for female genotype frequencies did not show deviation (p=0.29).Conclusions: The frequency of G6PD deficiency alleles in males in the Kavango and Zambezi regions of northern Namibia constitute 3.27%, a first report to inform policy on primaquine role out.